204 related articles for article (PubMed ID: 14583574)
1. Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis.
Tchetverikov I; Lard LR; DeGroot J; Verzijl N; TeKoppele JM; Breedveld FC; Huizinga TW; Hanemaaijer R
Ann Rheum Dis; 2003 Nov; 62(11):1094-9. PubMed ID: 14583574
[TBL] [Abstract][Full Text] [Related]
2. [Correlations between serum matrix metalloproteinase (MMP-1, MMP-3, MMP-9, MMP-13) concentrations and markers of disease activity in early rheumatoid arthritis].
Fiedorczyk M; Klimiuk PA; Sierakowski S; Domysławska I; Chwiećko J
Przegl Lek; 2005; 62(12):1321-4. PubMed ID: 16786739
[TBL] [Abstract][Full Text] [Related]
3. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
[TBL] [Abstract][Full Text] [Related]
4. Baseline serum level of matrix metalloproteinase-3 as a biomarker of progressive joint damage in rheumatoid arthritis patients.
Galil SM; El-Shafey AM; Hagrass HA; Fawzy F; Sammak AE
Int J Rheum Dis; 2016 Apr; 19(4):377-84. PubMed ID: 25292349
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers.
Young-Min S; Cawston T; Marshall N; Coady D; Christgau S; Saxne T; Robins S; Griffiths I
Arthritis Rheum; 2007 Oct; 56(10):3236-47. PubMed ID: 17907159
[TBL] [Abstract][Full Text] [Related]
6. MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis.
Tchetverikov I; Ronday HK; Van El B; Kiers GH; Verzijl N; TeKoppele JM; Huizinga TW; DeGroot J; Hanemaaijer R
Ann Rheum Dis; 2004 Jul; 63(7):881-3. PubMed ID: 15194590
[TBL] [Abstract][Full Text] [Related]
7. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis.
Cunnane G; Fitzgerald O; Beeton C; Cawston TE; Bresnihan B
Arthritis Rheum; 2001 Oct; 44(10):2263-74. PubMed ID: 11665967
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase-3 levels in relation to disease activity and radiological progression in rheumatoid arthritis.
Tuncer T; Kaya A; Gulkesen A; Kal GA; Kaman D; Akgol G
Adv Clin Exp Med; 2019 May; 28(5):665-670. PubMed ID: 30740946
[TBL] [Abstract][Full Text] [Related]
9. Serum matrix metalloproteinase 3 levels in comparison to C-reactive protein in periods with and without progression of radiological damage in patients with early rheumatoid arthritis.
Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH
Clin Exp Rheumatol; 2003; 21(4):465-72. PubMed ID: 12942698
[TBL] [Abstract][Full Text] [Related]
10. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis.
Green MJ; Gough AK; Devlin J; Smith J; Astin P; Taylor D; Emery P
Rheumatology (Oxford); 2003 Jan; 42(1):83-8. PubMed ID: 12509618
[TBL] [Abstract][Full Text] [Related]
11. Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with alpha2 macroglobulin in serum of rheumatoid arthritis patients.
Tchetverikov I; Kraan MC; van El B; Hanemaaijer R; DeGroot J; Huizinga TW
Ann Rheum Dis; 2008 Jan; 67(1):128-30. PubMed ID: 17875551
[TBL] [Abstract][Full Text] [Related]
12. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
13. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
[TBL] [Abstract][Full Text] [Related]
14. Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression.
Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH
J Rheumatol; 2000 Dec; 27(12):2761-8. PubMed ID: 11128661
[TBL] [Abstract][Full Text] [Related]
15. Association of tumor necrosis factor-α (G-308A) genetic variant with matrix metalloproteinase-9 activity and joint destruction in early rheumatoid arthritis.
Stojanovic S; Bojana Stamenkovic ; Stoimenov TJ; Nedovic J; Zivkovic V; Despotovic M; Pavlovic D
Clin Rheumatol; 2017 Jul; 36(7):1479-1485. PubMed ID: 28573370
[TBL] [Abstract][Full Text] [Related]
16. Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs.
Mamehara A; Sugimoto T; Sugiyama D; Morinobu S; Tsuji G; Kawano S; Morinobu A; Kumagai S
Kobe J Med Sci; 2010 Sep; 56(3):E98-107. PubMed ID: 21063156
[TBL] [Abstract][Full Text] [Related]
17. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis.
Yoshihara Y; Obata K; Fujimoto N; Yamashita K; Hayakawa T; Shimmei M
Arthritis Rheum; 1995 Jul; 38(7):969-75. PubMed ID: 7612046
[TBL] [Abstract][Full Text] [Related]
18. Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA.
Shinozaki M; Inoue E; Nakajima A; Hara M; Tomatsu T; Kamatani N; Yamanaka H
Mod Rheumatol; 2007; 17(5):403-8. PubMed ID: 17929133
[TBL] [Abstract][Full Text] [Related]
19. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis.
Yamanaka H; Matsuda Y; Tanaka M; Sendo W; Nakajima H; Taniguchi A; Kamatani N
Arthritis Rheum; 2000 Apr; 43(4):852-8. PubMed ID: 10765930
[TBL] [Abstract][Full Text] [Related]
20. Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up.
Houseman M; Potter C; Marshall N; Lakey R; Cawston T; Griffiths I; Young-Min S; Isaacs JD
Arthritis Res Ther; 2012 Feb; 14(1):R30. PubMed ID: 22314025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
